Invention Grant
- Patent Title: Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
-
Application No.: US14084047Application Date: 2013-11-19
-
Publication No.: US10208349B2Publication Date: 2019-02-19
- Inventor: Adam Samuel Platt , Stephen Edward Rapecki , Mara Fortunato , David Robert Rainey , Jon Leigh Rundle , Paul Alfred Smith , Gillian Sairfull Watt
- Applicant: UCB BIOPHARMA SPRL
- Applicant Address: BE Brussels
- Assignee: UCB BIOPHARMA SPRL
- Current Assignee: UCB BIOPHARMA SPRL
- Current Assignee Address: BE Brussels
- Agency: Marshall, Gerstein & Borun LLP
- Priority: GB1100282.1 20110107
- Main IPC: C12Q1/68
- IPC: C12Q1/68 ; G01N33/68 ; C12Q1/6883 ; C12Q1/6886
Abstract:
The present invention provides the use of lipocalin 2 (LCN2) as a biomarker for IL-17 mediated diseases and for monitoring the response of a patient to anti-IL-17 therapy.
Public/Granted literature
- US20140080134A1 LIPOCALIN 2 AS A BIOMARKER FOR IL-17 INHIBITOR THERAPY EFFICACY Public/Granted day:2014-03-20
Information query
